Romero-Gameros Carlos Alfonso, Vargas-Ortega Guadalupe, Rendón-Macias Mario Enrique, Cuevas-García Carlos Fredy, Colín-Martínez Tania, Sánchez-Hurtado Luis Alejandro, Balcázar-Hernández Lourdes Josefina, De la Cruz-Rodríguez Iván Emilio, Pérez-Dionisio Enid Karina, Retana-Torres Perla Michelle, García-Montesinos Elsy Sarahí, López-Moreno Mayra Alejandra, Intriago-Alor Marielle, Waizel-Haiat Salomón, González-Virla Baldomero
Otorhinolaryngology Service, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico.
Endocrinology Service, Hospital de Especialidades, Centro Médico Nacional Siglo XXI, Instituto Mexicano del Seguro Social, Mexico City 06720, Mexico.
J Clin Med. 2022 May 14;11(10):2780. doi: 10.3390/jcm11102780.
The presence of cardio-metabolic and respiratory comorbidities, immunosuppression, and chronic kidney disease have been associated with an increase in mortality from COVID-19. The objective of this study is to establish the risk factors associated with 30-day mortality in a cohort of hospitalized patients with COVID-19. This paper conducts a retrospective and analytical study of patients hospitalized for COVID-19 in a tertiary care center. A Cox proportional hazard analysis was performed to estimate the association of comorbidities with 30-day mortality. A total of 1215 patients with a median age of 59 years were included. In the adjusted Cox proportional hazards regression model, hypothyroidism, D-dimer ≥ 0.8 μg/mL, LHD ≥ 430 IU/L, CRP ≥ 4.83 ng/mL, and triglycerides ≥ 214 mg/dL were associated with an increased risk of death. The presence of a history of hypothyroidism and biomarkers (D-dimer, lactic dehydrogenase, CRP, and triglycerides) were associated with an increase in mortality in the studied cohort.
心血管代谢和呼吸系统合并症、免疫抑制以及慢性肾脏病的存在与新冠病毒疾病(COVID-19)导致的死亡率增加有关。本研究的目的是确定一组住院COVID-19患者中与30天死亡率相关的危险因素。本文对一家三级护理中心收治的COVID-19住院患者进行了回顾性分析研究。进行了Cox比例风险分析以评估合并症与30天死亡率之间的关联。共纳入1215例患者,中位年龄为59岁。在调整后的Cox比例风险回归模型中,甲状腺功能减退、D-二聚体≥0.8μg/mL、乳酸脱氢酶(LHD)≥430IU/L、C反应蛋白(CRP)≥4.83ng/mL以及甘油三酯≥214mg/dL与死亡风险增加相关。甲状腺功能减退病史以及生物标志物(D-二聚体、乳酸脱氢酶、C反应蛋白和甘油三酯)的存在与研究队列中的死亡率增加有关。